Shots:
- Alvotech has entered into a collaboration & license agreement with Dr. Reddy’s to co-develop, manufacture & commercialize a biosimilar version of Merck’s Keytruda (pembrolizumab) globally
- As per the deal, Alvotech & Dr. Reddy’s will jointly develop & manufacture the biosimilar candidate, sharing costs & responsibilities, with each retaining the right to commercialize it globally, subject to certain exceptions
- Pembrolizumab is a highly selective humanized mAb, which binds with PD-1 receptor to prevent its interaction with PD-L1 & PD-L2 ligands
Ref: GlobeNewswire | Image: Alvotech and Dr. Reddy’s | Press Release
Related News:- Alvotech Expands its Partnership with Advanz Pharma to Commercialize Three Additional Biosimilars in the EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
